Piramal Pharma FY2026 results: revenue, loss, board updates

Piramal Pharma Limited has reported its financial results for the year ended March 31, 2026, disclosing both standalone and consolidated numbers. The company posted standalone revenue of ₹4,782.01 crore for FY2026, while consolidated revenue stood at ₹8,869.08 crore. Alongside the audited financial disclosures, Piramal Pharma announced a set of board and management changes, including leadership re-appointments and a change in the company’s compliance function. These updates were made through stock exchange filings, with BSE cited as the source for the FY2026 results disclosure.

The announcements matter for investors because the results show a divergence between standalone profitability and consolidated losses, and because the board has also locked in leadership continuity through multiple re-appointments. The company has also scheduled an investor conference call for April 29, 2026, following the board’s consideration of audited results.

FY2026 audited results: headline numbers

For FY2026, Piramal Pharma reported standalone revenue of ₹4,782.01 crore. On a consolidated basis, revenue was ₹8,869.08 crore for the same period. In standalone performance, profit after tax (PAT) came in at ₹700.01 crore, compared with ₹691.40 crore in the previous year, indicating a modest increase year-on-year.

However, consolidated results showed a different outcome. Piramal Pharma reported a net loss after tax of ₹325.94 crore on a consolidated basis for FY2026. The company also disclosed an impairment charge of ₹175.82 crore recognised during the year, which it attributed to operational and exceptional items.

Standalone performance: PAT up versus previous year

The standalone numbers indicate that the company’s India entity reported improved profitability despite the broader group-level headwinds visible in consolidated accounts. Standalone PAT for FY2026 rose to ₹700.01 crore from ₹691.40 crore in the previous year. The disclosure did not detail the standalone margin drivers in the provided text, but the year-on-year comparison shows the base business remained profitable on a standalone basis.

From an interpretation standpoint, standalone profits often reflect the performance of the parent entity, while consolidated results include the effect of subsidiaries, overseas operations, and exceptional items. This gap between the two sets of numbers is relevant when investors assess cash generation, the contribution from international operations, and the impact of one-time charges.

Consolidated results: loss and impairment charge

On a consolidated basis, Piramal Pharma reported a net loss after tax of ₹325.94 crore for FY2026. The company’s filing noted that the loss reflected various operational and exceptional items and included an impairment charge of ₹175.82 crore recognised during the year. Impairment charges typically reduce reported profit and can reflect reassessments of asset values, but the filing excerpt did not specify the underlying assets or business unit related to the impairment.

The disclosure highlights that while revenue at the consolidated level was materially higher than standalone revenue, profitability was impacted by charges and other group-level costs. Investors generally track such items closely because they can affect reported earnings, leverage metrics, and the narrative around business performance.

Recent quarterly context from FY2026 disclosures

The company’s earlier communications during FY2026 provided additional context on operating conditions. For Q3 FY2026, Piramal Pharma reported consolidated revenue from operations of ₹2,140 crore, compared with ₹2,204 crore in Q3 FY2025, a decline of 3% year-on-year. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹6,117 crore versus ₹6,397 crore in the comparable period, down 4%.

In the Q3 and 9M FY2026 update, the company cited inventory destocking in one large on-patent commercial product by a customer, slower early-stage order inflows in H1 FY2026 due to inconsistent recovery in US biopharma funding, uncertainties on global trade policies, and regulatory delays in inhalation anesthesia for ex-US markets from the Digwal facility. It also stated that EBITDA margin pressure was partly offset by cost optimisation and operational excellence efforts. The company further noted “early signs of recovery” with a pick-up in RFPs and order inflows since October 2025, linked to improved biopharma funding and increased M&A activity in the US.

Leadership continuity: chairperson and directors re-appointed

Alongside the FY2026 financial results disclosure, Piramal Pharma confirmed key board decisions on leadership continuity. Ms. Nandini Piramal has been re-appointed as Whole-Time Director and designated as Executive Director and Chairperson for a further term of three years, starting April 1, 2027. The company also re-appointed Mr. Peter DeYoung as Whole-Time Director, designated as Executive Director, for a three-year term effective October 6, 2026.

The board additionally approved the re-appointment of Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five consecutive years, effective March 30, 2027. Separately, earlier exchange disclosures noted the cessation of Mr. Subramanian Ramadorai as an Independent Director with effect from February 9, 2026, upon completion of his term.

Company secretary transition and Mumbai office shift

Piramal Pharma also announced changes in its key managerial personnel and corporate administration. Mr. Maneesh Sharma has been appointed as the new Company Secretary and Compliance Officer, effective April 29, 2026. He will take over from Ms. Pratibha Mishra, who served as the interim lead, according to the disclosure.

The company further said it has updated its registered office address in Mumbai, effective April 30, 2026. The new address will be at the Ananta Building, Piramal Corporate Park. Such changes are typically relevant for statutory communications, regulatory filings, and shareholder correspondence.

Key dates: board meeting and conference call

Exchange filings also referenced the board meeting process leading up to the FY2026 results. Piramal Pharma informed BSE that a board meeting was scheduled on April 28, 2026, to consider and approve audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. In addition, the company scheduled a results conference call for April 29, 2026, from 9:30 AM to 10:15 AM IST, with dial-in details made available for multiple geographies.

The company also stated that pre-registration via a Diamond Pass link could reduce waiting time, as per the conference call note included in the provided text. The same set of updates mentioned a trading window closure from April 1, 2026 to April 30, 2026 (inclusive), aligned with typical compliance practices around financial results.

Summary table: FY2026 results and corporate actions

Market impact: what investors will track

The FY2026 disclosure sets up two immediate areas of focus for investors. First is the gap between standalone profit and consolidated loss, especially the role of the ₹175.82 crore impairment charge and other operational or exceptional items mentioned in the filing. Second is the operating context described in the company’s FY2026 communications, including customer destocking, biopharma funding-linked ordering patterns, and regulatory timelines for specific products and facilities.

Leadership and compliance appointments are also closely watched for continuity and governance, particularly for listed companies operating across multiple markets. With the results conference call scheduled for April 29, 2026, investors will look for additional clarity on the drivers behind the FY2026 consolidated loss, the nature of impairment, and the company’s commentary on order inflows and demand conditions referenced in FY2026 communications.

Conclusion

Piramal Pharma’s FY2026 update combined audited financial disclosures with a set of board and management actions. The company reported standalone revenue of ₹4,782.01 crore with standalone PAT of ₹700.01 crore, while consolidated revenue was ₹8,869.08 crore with a net loss of ₹325.94 crore that included an impairment charge of ₹175.82 crore. The board approved re-appointments for key directors and confirmed a new Company Secretary and Compliance Officer effective April 29, 2026, along with a registered office address change effective April 30, 2026.

The next confirmed milestone is the results conference call on April 29, 2026, where management commentary typically provides additional operational detail around the reported numbers and recent business conditions.